420786-92-1

Basic information

• Product Name: 2-Bromo-4-fluoro-5-methoxyaniline
• Synonyms: 2-Bromo-4-fluoro-5-methoxyaniline;2-Bromo-4-fluoro-5-(methyloxy)aniline;6-Bromo-4-fluoro-3-methoxyaniline;2-Bromo-4-fluoro-5-methoxy-phenylamine
• CAS NO: 420786-92-1
• Molecular Formula: C₇H₇BrFNO
• Molecular Weight: 220.0389832
• Mol File: 420786-92-1.mol

Chemical Properties

• Boiling Point: 290.6±35.0℃ (760 Torr)
• Flash Point: 129.6±25.9℃
• Appearance: /
• Density: 1.616±0.06 g/cm3 (20 ºC 760 Torr)
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• CAS DataBase Reference: 2-Bromo-4-fluoro-5-methoxyaniline(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Bromo-4-fluoro-5-methoxyaniline(420786-92-1)
• EPA Substance Registry System: 2-Bromo-4-fluoro-5-methoxyaniline(420786-92-1)

Safety Data

• Hazardous Substances Data: 420786-92-1(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
2-Bromo-4-fluoro-5-methoxyaniline is used as an intermediate in the synthesis of various organic compounds for pharmaceutical applications. Its unique structure allows for the development of new drugs with potential therapeutic benefits.
Used in Chemical Industry:
In the chemical industry, 2-Bromo-4-fluoro-5-methoxyaniline serves as a reagent in organic reactions, facilitating the synthesis of a wide range of chemical products. Its functional groups enable it to participate in various chemical transformations, contributing to the production of diverse compounds.
Used in Research and Development:
2-Bromo-4-fluoro-5-methoxyaniline is also utilized in research and development for studying its potential biological and pharmacological properties. Its unique structure and reactivity make it a valuable compound for exploring new avenues in drug discovery and chemical synthesis.
Safety Precautions:

Upstream product

• 64465-53-8 4-fluoro-3-methoxyaniline 
• 661463-13-4 4-bromo-2-fluoro-5-nitrophenyl methyl ether 

Downstream Products

• 864292-99-9 methyl 2-amino-5-fluoro-4-methoxybenzoate 
• 1363380-91-9 2-amino-5-fluoro-4-methoxybenzoic acid 
• 1416858-42-8 2-bromo-4-fluoro-5-methoxy-N-(9H-xanthen-9-ylidene)aniline 
• 661463-14-5 5-({[2-bromo-4-fluoro-5-(methyloxy)phenyl]amino}methylidene)-2,2-dimethyl-1,3-dioxane-4,6-dione 
• 420786-95-4 6-fluoro-2-methyl-quinolin-5-ol 

Relevant articles and documents

IMINO SULFANONE INHIBITORS OF ENPP1

The present disclosure relates generally to inhibitors of ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1), compositions thereof, and methods of using said compounds and compositions thereof. More specifically, the present disclosure relates to sulfoximine- based inhibitors of ENPP1 of Formula (I) and methods of their use for treating disease mediated by ENPP1.

9-SUBSTITUTED AMINO TRIAZOLO QUINAZOLINE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITIONS AND THEIR USE

In its many embodiments, the present invention provides certain 9-substituted amino triazolo quinazoline compounds of the structural Formula (I): (I), and pharmaceutically acceptable salts thereof, wherein, ring A, R1 and R2 are as defined herein, pharmaceutical compositions comprising one or more such compounds (alone and in combination with one or more other therapeutically active agents), and methods for their preparation and use, alone and in combination with other therapeutic agents, as antagonists of A2a and/or A2b receptors, and in the treatment of a variety of diseases, conditions, or disorders that are mediated, at least in part, by the adenosine A2a receptor and/or the adenosine A2b receptor.

INHIBITORS OF HEXOKINASE AND METHODS OF USE THEREOF

Provided herein are substituted substituted heterocycles useful as inhibitors of the HKII enzyme. The invention further provides pharmaceutical compositions of the compounds of the invention. The invention further provides medical uses of substituted heterocycles, for example, as antitumor agents.

Discovery of Potent and Selective Inhibitors for G9a-Like Protein (GLP) Lysine Methyltransferase

G9a-like protein (GLP) and G9a are highly homologous protein lysine methyltransferases (PKMTs) sharing approximately 80% sequence identity in their catalytic domains. GLP and G9a form a heterodimer complex and catalyze mono- and dimethylation of histone H3 lysine 9 and nonhistone substrates. Although they are closely related, GLP and G9a possess distinct physiological and pathophysiological functions. Thus, GLP or G9a selective small-molecule inhibitors are useful tools to dissect their distinct biological functions. We previously reported potent and selective G9a/GLP dual inhibitors including UNC0638 and UNC0642. Here we report the discovery of potent and selective GLP inhibitors including 4 (MS0124) and 18 (MS012), which are >30-fold and 140-fold selective for GLP over G9a and other methyltransferases, respectively. The cocrystal structures of GLP and G9a in the complex with either 4 or 18 displayed virtually identical binding modes and interactions, highlighting the challenges in structure-based design of selective inhibitors for either enzyme.

ANTIBACTERIAL AGENTS

Naphthalene, quinoline, quinoxaline and naphthyridine derivatives useful in the treatment of bacterial infections in mammals, particularly humans, are disclosed herein.

AMINOCYCLOHEXENE QUINOLINES AND THEIR AZAISOSTERIC ANALOGUES WITH ANTIBACTERIAL ACTIVITY

Cyclohexene derivatives and pharmaceutically acceptable derivatives thereof useful in methods of treatment of bacterial infections in mammals, particularly man.